AssetMark Inc
IMVT icon

AssetMark Inc’s Immunovant IMVT Stock Holding History

AssetMark Inc’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.78K Sell
112
-5
-4% -$197 ﹤0.01% 2842
2026
Q2 		$4.51K Hold
117
– – ﹤0.01% 2725
2026
Q1 		$2.91K Hold
117
– – ﹤0.01% 2744
2025
Q4 		$2.97K Buy
117
+5
+4% +$111 ﹤0.01% 2649
2025
Q3 		$1.8K Sell
112
-21
-16% -$340 ﹤0.01% 2648
2025
Q2 		$2.13K Sell
133
-2,188
-94% -$33.1K ﹤0.01% 2411
2025
Q1 		$39.7K Sell
2,321
-289
-11% -$6.05K ﹤0.01% 1503
2024
Q4 		$64.6K Sell
2,610
-281
-10% -$7.97K ﹤0.01% 1347
2024
Q3 		$82.4K Buy
2,891
+1,228
+74% +$36.2K ﹤0.01% 1182
2024
Q2 		$43.9K Buy
1,663
+24
+1% +$683 ﹤0.01% 1260
2024
Q1 		$53K Buy
1,639
+182
+12% +$6.64K ﹤0.01% 1152
2023
Q4 		$61.4K Buy
+1,457
New +$53.6K ﹤0.01% 1119

Other funds holding IMVT

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

AssetMark Inc's IMVT Position: Q3 2026 in Review

AssetMark Inc reduced its Immunovant (IMVT) stake by 4.3% in Q3 2026, selling an estimated $197 and leaving 112 shares worth $3.78K. The position accounts for ﹤0.01% of the portfolio, ranked #2842.

AssetMark Inc first reported a position in IMVT in Q4 2023 and has held it in 12 quarters since. The position peaked at $82.4K in Q3 2024. 72 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • AssetMark Inc held 112 shares of Immunovant worth $3.78K as of Q3 2026.
  • AssetMark Inc sold 5 Immunovant shares in Q3 2026, an estimated $197.
  • Immunovant made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #2842 holding.
  • AssetMark Inc first reported a position in Immunovant in Q4 2023 and has held it in 12 quarters since.
  • AssetMark Inc's Immunovant position peaked at $82.4K in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.